Compare HCC & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HCC | HAE |
|---|---|---|
| Founded | 2015 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.8B |
| IPO Year | 2017 | 1996 |
| Metric | HCC | HAE |
|---|---|---|
| Price | $89.46 | $121.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | $109.17 | ★ $124.50 |
| AVG Volume (30 Days) | 554.2K | ★ 620.2K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.03 | 0.72 |
| Revenue | ★ $1,310,043,000.00 | $910,373,000.00 |
| Revenue This Year | $52.73 | $6.21 |
| Revenue Next Year | $10.49 | $5.54 |
| P/E Ratio | ★ $29.66 | $168.90 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $61.87 | $48.98 |
| 52 Week High | $111.42 | $123.77 |
| Indicator | HCC | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 73.84 |
| Support Level | $82.72 | $100.92 |
| Resistance Level | $92.19 | N/A |
| Average True Range (ATR) | 3.19 | 3.29 |
| MACD | 0.24 | 1.22 |
| Stochastic Oscillator | 45.45 | 87.17 |
Warrior Met Coal Inc produces and exports met or steelmaking coal, which is used as a component for steel production by metal manufacturers in Europe, South America, and Asia. The company is involved in longwall mining operations in its underground mines based in Alabama, Mine No. 4, Mine No. 7, and Blue Creek. Additionally, its natural gas operations remove and sell natural gas from owned and leased coal seams by reducing natural gas levels in its mines. The company generates revenue mainly through the production of steelmaking coal for sale to the steel industry. Geographically, the firm generates maximum revenue from its customers in Asia, followed by Europe, South America, and the United States.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.